Figure 2. Remission rates at month 0 and month 12 in the efficacy and “per-protocol” populations following treatment with MMX mesalazine 2.4 g/day given once daily or twice daily.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.